Manremyc, a company with a unique and revolutionary product: Nyaditum resae® (NR), based on the most updated technology and a solid scientific background.
WE ARE HERE TO SERVE YOU
We are a Company with the mission to eradicate tuberculosis (TB) by reducing its risk of development with a unique and revolutionary product (Nyaditum resae® (NR)) based on the most updated technology and a solid scientific background.
Manremyc was founded and is actually supported by the Experimental Tuberculosis Unit, a scientific team leader of TB research in Europe with a well-reknown history of publications; international public and private fundings; and the experience of having successfully participated in drug and vaccine development (including the design and development of the first therapeutic vaccine against TB (RUTI®, now developed by ArchivelFarma SL).
Besides the scientific founder team, Manremyc is nowadays integrated by a complex multi-skilled team involving private investors and a group of providers including production, regulatory and business experts that make possible the development of NR.
MEET OUR VALUABLE TEAM MEMBERS
MANREMYC was founded with the aim of eradicating TB reaching out to most neglected populations. We are implementing multi-stakeholder business model to make N.R available, accessible, affordable and accepted by deprived communities. To achieve our vision, we are enabling social innovative processes where private-public partnerships are a cornerstone The aim of the company is to help people with a benefit for their health, a big aim with a big heart. For being a natural non-pharma product, NR can be in the market now, everywhere, worldwide distributed, arriving even to the most forgotten populations at risk of TB.
Nyaditum resae® is designed to face a major humankind problem, which is tuberculosis (TB). TB is a infectious disease which continues to kill 1·4 million people annually, striking severly Africa and Asia. Caused by a bacillus called Mycobacterium tuberculosis, one gets infected when the bacteria is transmitted from an ill person while talking, singing, coughing or sneezing. Once infected, the disease can remain silent for years, but suddenly to cause severe symptomatology and even death without treatment.
We have discovered that with the induction of an specific balanced immune response, the exaggerated inflammatory response triggered by the body against the bacilli can be modulated, and the development of TB avoided. This can be generated by “educating” the immunity of the host to not consider the bacilli as a danger, but as a food. With this purpose, we have developed Nyaditum resae ® (NR), to be given in low doses daily for short periods of time (2 weeks) and able to generate this balanced immune response.
NR is a revolutionary product: a nutraceutical with natural origin, a low-cost production, well-tolerated and safe. For being a probiotic, NR is not submitted to the regulatory restrictions of drugs and is already available in the market.
Of oral administration, several available marketed forms and low price, NR is easy to be distributed and can be included in massive health interventions.
NR IN THE MARKET
NR is a unique product: there is no other natural product with a high-quality scientific background and technically developed in excellence (in terms of efficacy and toxicity assays) without being a drug. However, there are some other therapeutic approaches available in the TB market :
1.- Antibiotics. Isoniazid is prescribed to reduce the risk of developing an active TB once infected, thus antibiotics could be competitors of NR if there was any screening of infection. However, most countries at risk of TB have a such a high TB incidence that the screening is not economically viable and therefore not mandatory and not done. NR instead, can be offered to anyone at risk, without prior knowing if this person is already infected or not.
2.- Other host directed therapies, like Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or vitamin D. Recent scientific advances in TB field have revealed the immunomodulation of the response to TB with host-directed therapies could be the clue to control the disease. However, approaches as NSAIDs have a range of well-known adverse effects and the scientific community has still not agreed on which length would ideally have the treatment to achieve efficacy. Moreover, the dose and adverse effects of vitamin D which might be useful are still under discussion. NR for its natural characteristics and manufacturing processes, NR is a totally safe product.
SCIENTIFIC & TECHNICAL DETAILS
Nyaditum resae ® (NR) is the product able to induce the balanced immune response that diminish the risk of acquiring TB. Its production is based in the elaboration of a heat-killed culture of and environmental micobacteria belonging to the family of Mycobacterium fortuitum complex (new species: Mycobacterium manresensis). The final active ingredient is a powder in which a known concentration of a low dose heat-killed bacteria plus and excipient, and can be distributed in different final forms. After giving it daily for 14 days, it has been demonstrated that is able to stop the progression towards active TB in preclinical assays.
Safety has been demonstrated both in preclinical assays and in a clinical trial. The preclinical and clinical assays have been presented in several scientific international meetings, and the technology of NR is patented (PCT/ES2013/000145).
“Nyaditum resae®, a new immunomodulatory compound to control active tuberculosis (TB), safe and well-tolerated in a Clinical Trial“. 45th Union World Conference on Lung HealthBarcelona, Spain. 28th Oct-1st Nov 2014.
“Nyaditum resae®, a new immunomodulatory compound to prevent and treat active tuberculosis (TB)”. Elena Marzo; Paula Cardona; Jorge Diaz; Vanessa Garcia; Sonia Rebollo; AntoniPlanella; Cristina Vilaplana; Pere-Joan Cardona. 9th International Conference on the Pathogenesis of Mycobacterial Infection. Oral communication. Saltsjöbaden, Sweden. June, 2014.
“Nyaditum resae®, a diet complement to reduce the risk of progressing to active disease “. P-J Cardona. 6th June, 2014. Mycoval congress. Valencia, Spain. Invited Conference.
“Safety and Immunogenicity of NyaditumResae® Probiotic to Protect From Tuberculosis” Clinical Trial. ClinicalTrials.gov Identifier: NCT02076139
You can directly contact our Project Manager, Mr Eloi Lukacs. We will be happy to answer your questions. Thank you for your interest!
Manresana de Micobacteriologia, sl
C/Urgell nº 26, 1
VAT number: B66008095
CONTACT US at elukacs @ manremyc.cat